Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance

checkorphan
Learn more about:
Patent ductus arteriosus
Related Clinical Trial
Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen Aminoglycosides and Duct Radiation-Free Heart Catheterization Using MRI Hemodynamic Responses to Cardio-respiratory Events in Preterm Infants Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease The Preterm Infants’ Paracetamol Study Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants Evaluation of the Brain and Renal Regional Oxygenation Using NIRS in Preterm Infants Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD Hyperion™ International Registry Trial NIRS in PDA VLBW Infants Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance Comparison of Oral and Intravenous Ibuprofen for PDA Treatment in Premature Infants The Impact of Platelet Functions on Spontaneous Ductal Closure in Preterm Infants Lifetech CeraFlex™ Post-Market Surveillance Study Treatment of a PDA With Acetaminophen in Preterm Neonates: Exploring Various Indications Nit-Occlud PDA Post-Approval Study Ibuprofen and Renal Function in Premature Infants A New Device for Measuring of Lung Photoplethysmography and Pulmonic Arterial Saturation Canadian National PDA Treatment Study Long Term Results of 450 Percutaneous Closures of PDA in a Single Center Efficacy and Safety of Oral Versus Intravenous Ibuprofen for PDA Treatment in ELBW Infants AMPLATZER Duct Occluder II Additional Sizes A NEW SCORING SYSTEM FOR PREDICTION OF PDA Clinical Trial to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants The Efficacy of Implementing a Treatment Algorithm in Managing Patent Ductus Arteriosus (PDA) in the Extremely Low Birth Weight Neonatal Population. Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA) Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA Addition of Acetaminophen in Standard PDA Management Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA) Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates Paracetamol Versus Ibuprofen for PDA Closure Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Children With PDA Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm Infants Early Treatment Versus Expectative Management of PDA in Preterm Infants International Experience in Timing And Choices for Ductal Closure in Patent Ductus Arteriosus:INTERPDA Trial Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants Do Elevated BNP Levels Predict Hemodynamically Significant PDAs The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants Brain, Gut and Kidney Blood Flow During Medical Closure of PDA Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Labour at Term AMPLATZER Duct Occluder II Clinical Study The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Preterm Birth Paracetamol and Patent Ductus Arteriosus (PDA) Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at Near Infrared Spectroscopy to Determine Patent Ductus Arteriosus Closure Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure Pocket Echocardiography System (PES) for Detection of PDA in Neonates Treating the Resistant Patent Ductus Arteriosus (PDA) Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus IV Acetaminophen and Patent Ductus Arteriosus Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder Closure of Patent Ductus Arteriosus With Indomethacin or Ibuprofen in Extreme Low Birth Weight Infants Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI) Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants Patent Ductus Arteriosus and Splanchnic Oxygenation at First Feed Preliminary Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low-weight Infants Non-Invasive Detection of Tissue Oxygen Deprivation in Premature Infants With Patent Ductus Arteriosus. Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus Arteriosus

Brief Title

Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance

Official Title

Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance

Brief Summary

      The purpose of this post-marketing clinical use database surveillance is to observe the
      frequency, type, and degree of adverse device effects and adverse events in order to assure
      the safety of the medical device, and to collect safety and efficacy information for
      evaluating the results of its clinical use.

Detailed Description

      The Surveillance will be conducted per the standards required by the Ministry of Health,
      Labour and Welfare (MHLW) and in the standards for post-marketing surveillances and studies
      [except for those defined in the Ministerial Ordinance on Good Clinical Practice for Medical
      Devices (MHLW Ordinance No. 36, 2005)] based on Paragraph 4, Article 23-2-9 (including
      application mutatis mutandis per Article 23-2-19 of Revised PAL) of the Law on Securing
      Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices, etc. (Law No. 145, 1960,
      hereinafter referred to as "Revised PAL") by the Marketing Authorization Holder or accredited
      foreign manufacturer of a medical device defined in Paragraph 1, Article 23-2-5 of Revised
      PAL.

Study Type

Observational [Patient Registry]

Primary Outcome

The rate of major complications through 180 days after an attempted Piccolo device implant

Condition

Patent Ductus Arteriosus

Intervention

Amplatzer Piccolo Occluder

Study Arms / Comparison Groups

 Amplatzer Piccolo Occluder
Description:  Amplatzer Piccolo Occluder device implant

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Device

Estimated Enrollment

70

Start Date

April 1, 2020

Completion Date

May 31, 2025

Primary Completion Date

October 31, 2022

Eligibility Criteria

        Inclusion Criteria:

        The device is used to percutaneously close the PDA of a patient who meets all of the
        following:

          -  PDA ≤4 mm in diameter

          -  PDA ≥3 mm in length

          -  Weight ≥700 g

        Exclusion Criteria:

          -  Age <3 days

          -  Coarctation of the aorta

          -  Left pulmonary artery stenosis

          -  Cardiac output that is dependent on right to left shunt through the PDA due to
             pulmonary hypertension

          -  Thrombus in the implant site, or sign of venous thrombus in a vessel in which the
             occluder is inserted and delivered

          -  Endocarditis, or infection that can cause bacteremia

          -  Allergic or potentially allergic to nickel

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

, +81-3-3524-1792, [email protected]

Location Countries

Japan

Location Countries

Japan

Administrative Informations

NCT ID

NCT04371081

Organization ID

ABT-CIP-10290

Responsible Party

Sponsor

Study Sponsor

Abbott Medical Devices

Collaborators

 Japanese society of Congenital Interventional Cardiology

Study Sponsor

, ,

Verification Date

April 2020